This 2026 epigenetic lexicon compiles 45 fundamental concepts spanning from DNA methylation to sirtuines, including TADs, X-inactivation, and epigenetic aging. Epigenetics, positioned at the intersection of genetics and cellular biology, examines mechanisms that modulate gene expression without altering DNA sequences. These mechanisms, such as methylation and histone modifications, function as molecular switches, influencing organismal development, environmental adaptation, and intergenerational trait transmission. Each term is explained accessibly yet precisely, accompanied by concrete examples and health implications. The lexicon serves as an essential reference guide for students, researchers, and life sciences enthusiasts seeking to understand how molecular processes like acetylation and RNA interference regulate gene activity and contribute to conditions ranging from cancer to neurodegenerative diseases, offering insights into cutting-edge epigenetic discoveries.

A Boston-based biotech company has initiated the first human clinical trial of cellular reprogramming therapy, marking a significant milestone in reversing cellular aging. The treatment, called ER-100, targets age-related vision loss and glaucoma by reprogramming aged cells toward a younger state through epigenetic restoration. Developed by Life Biosciences, cofounded by geneticist David Sinclair, the therapy employs a modified virus to deliver three carefully designed genes—OCT4, SOX2, and KLF4—that reset cellular clocks. The eye was strategically chosen as the initial testing ground due to its relative isolation from the body, minimizing potential systemic adverse effects. This approach builds on Nobel laureate Shinya Yamanaka's pioneering work and prior Harvard laboratory studies demonstrating successful neuronal regeneration and vision restoration in glaucoma-affected mice.

Life Biosciences announced on June 9, 2026, that the first patient received ER-100, an experimental gene therapy designed to reverse cellular aging in a groundbreaking phase 1 clinical trial approved by the FDA in January. The therapy targets two optic nerve diseases—open-angle glaucomna and anterior ischemic optic neuropathy—major causes of adult blindness with no existing regenerative treatments. ER-100 works through partial epigenetic reprogramming, using three transcription factors injected into the eye to reactivate molecular mechanisms in damaged optic nerve cells, restoring them to a younger functional state without regression to stem cells that could trigger tumors. Building on David Sinclair's 2020 Harvard research demonstrating similar results in mice and primates, this trial represents the first human application of cellular rejuvenation technology. The eye's partial isolation from the body provides a controlled experimental environment, minimizing potential systemic side effects.

Life Biosciences, a Boston-based biotechnology firm, has achieved a groundbreaking milestone by administering the first human treatment designed to reverse cellular aging. The therapy, designated ER-100, utilizes three proteins known as OSK factors to perform partial epigenetic reprogramming, effectively resetting cellular age and restoring function in damaged or aging cells. Specifically targeting optic neuropathies characterized by optic nerve damage, this gene therapy delivers genetic instructions that act as a cellular reset mechanism. Following successful trials in rodents and primates, the company has announced the treatment of the first human patient, representing the inaugural approved epigenetic restoration candidate in clinical trials and potentially the first demonstration of human cellular rejuvenation if successful.

Multiple sclerosis (MS) is a central nervous system inflammatory autoimmune disease resulting from the interaction between genetic susceptibility and environmental factors, particularly geographic and viral influences. The condition involves two distinct inflammatory mechanisms: acute peripheral inflammation characterized by demyelinating plaques disseminated throughout the central nervous system, which manifests as sudden disease relapses, and chronic compartmentalized inflammation described as a "slow-burning" process that drives progressive clinical deterioration and neurodegeneration with atrophy. Affecting approximately three million people globally, MS represents the leading cause of non-traumatic neurological disability in adults within industrialized countries, with France reporting nearly 116,000 recognized cases in 2022.

Life Biosciences announced on June 9, 2026, that the first patient received ER-100, an experimental gene therapy designed to reverse cellular aging. This phase 1 trial, FDA-approved in January, addresses two optic nerve conditions—open-angle glaucoma and anterior ischemic optic neuropathy—major causes of adult blindness for which no existing treatments can regenerate destroyed neurons. The therapy employs partial epigenetic reprogramming, injecting three transcription factors directly into the eye via gene therapy vector to reactivate dormant molecular mechanisms in adult cells, restoring damaged optic nerve cells to a younger functional state without regressing to stem cell stages that could trigger tumors. Building on Harvard geneticist David Sinclair's landmark 2020 research demonstrating this gene combination regenerates optic nerves and restores vision in aged and glaucomatous mice, Life Biosciences successfully reproduced results in primates without serious adverse effects. The eye provides a relatively controlled experimental environment, partially isolated from systemic circulation, limiting potential side effects.

La sclérose en plaques est une maladie auto-immune qui touche le cerveau et qu'on ne sait toujours pas vraiment guérir. La mise sur le marché d'un nouveau traitement vient d'être validée par les autorités sanitaires européennes.

Aging is a complex biological process involving progressive decline in physiological function, driven by accumulation of cellular and molecular damage across multiple levels. While researchers have identified key hallmarks of aging including genomic instability, telomere attrition, and mitochondrial dysfunction, clinical practice has traditionally relied on chronological age as the primary metric for understanding aging. However, chronological age oversimplifies this multifactorial phenomenon and fails to account for significant individual variations in the aging process. This reliance stems from the historical absence of reliable biomarkers and measurement methods. Consequently, chronological age serves as an imperfect proxy for functional capacity and health vulnerability, as individuals of the same age often exhibit markedly different physiological states and health outcomes. Understanding the causal mechanisms underlying aging requires moving beyond chronological age toward more sophisticated, personalized measures of biological aging.

I cannot provide a summary for this article because the content provided only shows a redirect page without the actual article text. To write an accurate and informative professional summary, I would need access to the full article content discussing the relationship between Epstein-Barr virus and multiple sclerosis. Please provide the complete article text, and I will be happy to create a comprehensive 100-word summary suitable for a professional intelligence platform.

Multiple sclerosis research is advancing significantly through new diagnostic methods and treatment approaches. Scientists are developing disease-modifying therapies and exploring experimental stem cell treatments to better manage inflammation, protect nerves, and repair myelin damage, particularly for progressive MS patients. Genetic research has revealed that specific gene variants can influence MS progression rates and disease severity. A recent 2023 study found that individuals carrying certain genetic markers required mobility assistance approximately 3.7 years earlier than those without these variants, suggesting genes play a crucial role in the brain's capacity to manage MS damage. Diagnosis continues to rely on MRI imaging, blood tests, and spinal fluid analysis. While stem cell therapy remains experimental and not yet widely available, ongoing research into genetic factors and innovative treatment modalities offers promising potential for improving patient outcomes and understanding disease mechanisms.

Researchers have developed a groundbreaking approach to reverse cellular aging by resetting the epigenetic clock through partial epigenetic reprogramming (PER). Unlike previous full reprogramming methods that transformed adult cells into blank slates but risked uncontrolled differentiation, PER rejuvenates aged cells while preserving their identity and function. This technique works by erasing epigenetic changes accumulated over time without compromising cellular characteristics. Life Biosciences is advancing this technology with ER-100, entering the first-in-human study for treating optic neuropathies. The therapeutic potential extends beyond vision restoration, promising broader clinical applications in addressing age-related cellular decline and potentially revolutionizing regenerative medicine.

Despite major advances in therapy for multiple sclerosis (MS) patients, substantial unmet needs remain, particularly regarding the prevention of disability progression and the treatment of progressive and aggressive forms of the disease. While early use of high-efficacy therapies has improved inflammatory disease control, their impact on long-term neurodegeneration is limited, and therapeutic options for progressive MS remain scarce. Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a highly effective escalation strategy for selected patients with aggressive, inflammatory MS.

Researchers from Yale School of Medicine have identified a genetically driven immunologic mechanism linking Epstein-Barr virus (EBV) infection to multiple sclerosis development. This collaborative study, involving international institutions, elucidates how genetic factors predispose individuals to MS through EBV-triggered immune responses. The findings represent a significant advancement in understanding the molecular basis of MS pathogenesis, potentially opening new therapeutic avenues for prevention and treatment. By establishing this mechanistic link between viral infection and autoimmune disease, the research contributes valuable insights into how environmental and genetic factors converge in neurological disease development.

This comprehensive review examines how innate immunity fundamentally regulates adaptive immune responses through multiple interconnected mechanisms. The authors elucidate three primary pathways: remodeling of antigen presentation and costimulation, cytokine-mediated T helper cell polarization, and metabolic-epigenetic programming associated with trained immunity. The framework identifies three critical regulatory dimensions of innate immune signaling: insufficient activation impairs pathogen control and adaptive priming, excessive persistent activation drives autoimmune inflammation, and type 2-biased signaling promotes allergic responses. By integrating molecular signaling, cell crosstalk, metabolic regulation, and epigenetic remodeling, this review provides a unified understanding of how innate immune dysfunction contributes to adaptive immune dysregulation in infection, autoimmunity, and allergic diseases, while identifying therapeutic targets including interferon pathways, inflammasomes, and metabolic programs.

Multiple sclerosis, once thought to develop in an isolated brain, is increasingly recognized as influenced by complex environmental interactions. Despite skull and blood-brain barrier protection, the brain constantly adapts to external factors affecting disease development and progression. Research identifies several environmental contributors to MS risk, including viral infections like Epstein-Barr virus, vitamin D deficiency from limited sun exposure, and gut microbiota composition. Additional factors include dietary patterns, obesity, hormonal fluctuations, smoking, stress, air pollution, and temperature variations. The disease predominantly affects women and represents the leading cause of disability in young adults outside traumatic injuries, with higher prevalence in regions distant from the equator. Understanding these environmental-genetic interactions is crucial for comprehending MS pathogenesis and developing preventive strategies.

Aging represents a complex biological process characterized by progressive functional decline that drives the incidence of age-related diseases, including neurodegeneration, metabolic disorders, and cardiovascular conditions. Current therapeutic strategies target core aging hallmarks such as cellular senescence, metabolic dysfunction, epigenetic alterations, and mitochondrial impairment. Three primary approaches show considerable promise: senolytics eliminate senescent cells, senomorphics inhibit senescence-associated secretory phenotype, and senoreversion rejuvenates senescent cells through epigenetic reprogramming. Metabolic interventions, including caloric restriction mimetics like spermidine and α-ketoglutarate, enhance mitochondrial function and activate autophagy, demonstrating lifespan extension in preclinical models. Collectively, these emerging interventions facilitate the transition toward precision longevity medicine while leveraging artificial intelligence to accelerate therapeutic discovery through multiomics integration.

Imagine if multiple sclerosis (MS) became as rare as polio. It sounds absurd. MS is chronic, unpredictable, and devastating. We’ve spent decades throwing immunosuppressants, monoclonal antibodies, and remyelination therapies at it. But no matter how advanced our treatments have become, they all manage the disease, not the cause. That might be about to change.

Researchers from the Garvan Institute of Medical Research have conducted an unprecedented analysis of over 1.25 million blood cells from nearly 1,000 participants to elucidate why women experience higher rates of autoimmune diseases. Using single-cell RNA sequencing, the team identified over 1,000 genetic switches in immune cells that function differently based on sex. These variations in gene expression indicate that inflammatory pathways responding to threats are more active in women, increasing susceptibility to conditions such as lupus and multiple sclerosis. The findings underscore the critical importance of incorporating sex-based considerations into immune system research and clinical treatment development. This pioneering study addresses a significant gap in medical research by examining individual cell-level differences rather than averaging gene activity across mixed cell populations, potentially revolutionizing our understanding of sex-specific disease mechanisms.

Researchers from the Garvan Institute and UNSW Sydney have identified over 1,000 genetic switches that function differently between female and male immune cells, providing crucial insights into why women are significantly more susceptible to autoimmune diseases such as lupus and multiple sclerosis. The study, published in The American Journal of Human Genetics, reveals that female immune systems exhibit higher inflammatory pathway activity, making them more prone to mistakenly attacking healthy body tissues. These findings underscore a critical gap in medical research, which has historically focused on male cohorts, and emphasize the necessity of considering sex differences in understanding disease mechanisms and developing effective treatments.

Recent research has established Epstein-Barr virus as a pivotal factor in multiple sclerosis pathogenesis. Dr. Micah Luftig presents mechanistic insights into the EBV-MS relationship, highlighting its significance for clinical risk stratification and early intervention strategies. The emerging evidence suggests that EBV-targeted therapeutic approaches may fundamentally reshape future MS treatment protocols. Understanding the molecular mechanisms linking viral infection to neuroinflammatory cascade activation is crucial for developing preventive and therapeutic interventions. These findings have substantial implications for clinicians managing MS patients and may inform personalized medicine approaches based on individual EBV serostatus and immune profiles.